Omeros Corporation (NASDAQ: OMER) shares are trading higher by $0.49 (7 percent) at $8.10 in Thursday's session. The issue is getting a lift from data surrounding its OSM721 Phase 2 trial that showed "targeted indications for the company's MASP-2 inhibitor continue to expand."

On Monday, the issue rallied to $8.70 off the positive data, but faded to end the session at $7.60.

Over the last five trading sessions (including today), the issue has found support in the lower to middle $7 handle, with all five lows ranging from its October 14 low ($7.26) to today's low ($7.61).

So far, the rally off the low has reached $8.28, which represents its highest level since peaking on Monday. If Omeros can close over $8, it will be the first time doing so since its October 11 close of $8.61.